Amgen
Amgen’s Humira biosimilar succeeds in Phase III arthritis study
November 16, 2015Research and Development, Sales and Marketing Amgen, Humira
Amgen says its Humira (adalimumab) biosimilar candidate ABP 501 proved its clinical equivalence to Abbvie’s blockbuster drug in a head-to-head …
FDA approves first-in-class Amgen melanoma drug
October 28, 2015Research and Development, Sales and Marketing Amgen, Imlygic, melonoma
The US Food and Drug Administration (FDA) has approved Amgen’s Imlygic for the treatment of melanoma lesions in the skin …
Amgen skin cancer drug gets European approval
October 23, 2015Research and Development Amgen, Imlygic, melanoma, skin cancer
Amgen’s Imlygic (talimogene laherparepvec) has been approved by the scientific committee of the European Medicines Agency (EMA) for the treatment of adults …
FDA accepts Sandoz submission for Amgen biosimilar
October 2, 2015Medical Communications, Research and Development Amgen, FDA, Novartis, Sandoz, biosimilars
Sandoz, a Novartis company and a global leader in biosimilars, has announced today that the US Food and Drug Administration …
Amgen’s Kyprolis gets accelerated FDA review for expanded labelling
September 21, 2015Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma
The FDA has accepted for priority review Amgen’s supplemental new drug application for Kyprolis (carfilzomib) for patients with relapsed multiple …
Amgen joins M&A rush with deals for Dezima and Xencor
September 16, 2015Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation
Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …
AstraZeneca purchases former Amgen US facility
September 15, 2015Manufacturing and Production Amgen, AstraZeneca, US, biologics, manufacturing, production
AstraZeneca has bolstered its US presence with the purchase of a high-tech biologics manufacturing facility from pharma rival Amgen. The …
Sandoz launches first US biosimilar
September 3, 2015Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim
Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …
Amgen and Novartis partner on Alzheimer’s and migraine treatments
September 2, 2015Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience
Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine. The companies plan …
FDA approves Amgen’s cholesterol lowering drug
August 28, 2015Medical Communications, Research and Development Amgen, FDA, Repatha, evolocumab
The FDA has endorsed Amgen’s cholesterol-lowering medication, Repatha, for the use in patients with high cholesterol. It follows Amgen’s successful …
Amgen agrees to $71m settlement over false advertising
August 19, 2015Sales and Marketing Amgen, Aranesp, Enbrel
Amgen has reached a $71 million settlement with 48 US states and the District of Columbia, to resolve allegations that …
Amgen’s Repatha wins PCSK9 heart drug race
July 21, 2015Sales and Marketing Amgen, European Commission, PCKS9, Repatha, evolocumab, high cholesterol
The European Commission has signed off on Amgen’s Repatha, making it the first in a new class of cholesterol-lowering drugs …
Amgen bets on immunotherapy future
June 15, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, immunotherapy, oncology, oncolytic, tom lillie
When we speak to Tom Lillie he’s brimming with excitement about the future for Amgen in oncology and the future …
Amgen and Novartis tussle over biosimilar injunction
June 4, 2015Sales and Marketing Amgen, FDA, Neupogen, Novartis
Novartis has begun its court battle with Amgen over its biosimilar of cancer drug Neupogen, which Amgen is trying to …
Amgen hires head of Europe from Roche
June 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Corinne Le Goff, Roche
Corinne Le Goff is joining Amgen to be its senior vice president and head of the European region for the …
Latest content
Cytomos appoints life sciences executive to board
Scots neonatal innovations target hearing loss and earlier care
